Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

176
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
176
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

206
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
206
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

209
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
209
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

245
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
245
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.2K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asiatic acid promotes CD8<sup>+</sup> T cell-mediated antitumor immunity by targeting HDAC8/CXCL10 axis in hepatocellular carcinoma.

Acta pharmacologica Sinica·2026
Same author

Mitochondria-derived peptides in liver disease: Emerging regulators of hepatic metabolism and therapeutic targets.

Hepatology communications·2026
Same author

Dynamics of Serum Hepatitis B Virus Nucleic Acids in Patients With Chronic Hepatitis B After Stopping Nucleos(t)ide Analogs Reveal Delayed Rebound of Hepatitis B Virus RNA.

Journal of medical virology·2025
Same author

Improving Performance of Quasi-2D Perovskite Light-Emitting Diodes by Solvent Atmospheric Post-Treatment.

ACS applied materials & interfaces·2025
Same author

Non-coding RNAs in alcohol-associated liver disease.

Liver research (Beijing, China)·2025
Same author

Pd-Catalyzed Tandem Reaction of [1,1'-Biaryl]-2,2'-dimethylnitriles with Arylboronic Acids: Synthesis of 7-Aryl-2<i>H</i>-azepin-2-ones.

The Journal of organic chemistry·2025
Same journal

Navigating Chronic Pain in Patients with Cirrhosis: Unique Analgesic Considerations and Non-Pharmacologic Options.

Current hepatology reports·2026
Same journal

AIH Therapy: Beyond First‑Line.

Current hepatology reports·2026
Same journal

Transient Elastography and Fibroscan: Stethoscope of a Hepatologist in Today's World.

Current hepatology reports·2026
Same journal

Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?

Current hepatology reports·2025
Same journal

Outcomes in Cirrhosis-Related Refractory Ascites with Emphasis on Palliative Care: Single-Centre Experience and Literature Review.

Current hepatology reports·2025
Same journal

Hepatic Hydrothorax: A Review.

Current hepatology reports·2025
See all related articles

Related Experiment Video

Updated: Jan 12, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K

Alcohol-Associated Hepatitis: Translating Pathophysiology into Targeted Clinical Trials.

Jing Ma1, Hui Gao1, Ge Zeng1,2

  • 1Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, IN 46202 USA.

Current Hepatology Reports
|October 30, 2025
PubMed
Summary
This summary is machine-generated.

Alcohol-associated hepatitis (AH) is a severe liver disease with limited treatments. Research is exploring new therapies targeting oxidative stress, regeneration, and gut health to improve outcomes for patients with alcohol-associated hepatitis.

Keywords:
Alcohol-associated hepatitisClinical trialTherapeutic targets

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.5K

Related Experiment Videos

Last Updated: Jan 12, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.5K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Pharmacology

Background:

  • Alcohol-associated hepatitis (AH) is a severe form of alcohol-associated liver disease.
  • It is characterized by high short-term mortality and a lack of effective treatments.

Purpose of the Study:

  • To review the mechanisms underlying AH pathogenesis.
  • To evaluate past and emerging clinical trials for targeted therapeutic development.

Main Methods:

  • Synthesis of mechanistic insights into AH.
  • Evaluation of clinical trial data for various therapeutic targets.

Main Results:

  • AH pathogenesis involves hepatotoxicity, oxidative stress, inflammation, impaired regeneration, and gut-liver axis disruption.
  • Previous trials targeting inflammation or apoptosis showed no survival benefit and raised safety concerns.
  • Emerging therapies focus on mitigating oxidative stress, enhancing regeneration, and restoring gut integrity, including agents like IL-22, G-CSF, probiotics, FMT, larsucosterol, and FXR agonists.

Conclusions:

  • Understanding AH biology provides a basis for mechanism-based therapeutic strategies.
  • Integrating hepatology with addiction medicine and using stratified trial designs are crucial for advancing effective treatments.